Nancy A. Melville June 09, 2023 UPDATED June 12, 2023 // Editor’s note: This story has been updated with additional comments from Dr Ahmed Obeidat from the Medical College of Wisconsin. Frexalimab, a novel, second-generation anti-CD40L antibody, shows “strikingly positive” effects in the treatment of relapsing multiple sclerosis (MS), significantly reducing disease activity. “We should be very excited about these results,...